NICE - Endorsed Technology Appraisals 2023/2024

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.  The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2023/2024

The following technology appraisals have been endorsed during 2022/23. Information on technology appraisals endorsed in previous years can be found on the homepage. 

August 2023

TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer

TA909 - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy

‘Note this guidance updates and replaces NICE Technology Appraisal TA620, endorsed by the DoH in February 2020.’

TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis

TA906 - Rimegepant for preventing migraine

July 2023

TA905 - Upadacitinib for previously treated moderately to severely active Crohn’s disease

TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer

TA903 - Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer

TA902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

TA900 - Tixagevimab plus cilgavimab for preventing COVID-19

TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

June 2023

TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma

‘Note this guidance updates and replaces NICE Technology Appraisal TA573, endorsed by the DoH in May 2019.’

TA896 - Bulevirtide for treating chronic hepatitis D

TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma

TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over

TA892 - Mosunetuzumab for treating relapsed or refractory follicular lymphoma

TA891 - Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

TA890 - Difelikefalin for treating pruritus in people having haemodialysis

TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease

TA887 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

‘Note this guidance updates and replaces NICE Technology Appraisal TA831, endorsed by the DoH in October 2022.’

TA886 - Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

May 2023

TA885 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

TA883 - Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

TA882 - Voclosporin with mycophenolate mofetil for treating lupus nephritis

TA881 - Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments

TA880 - Tezepelumab for treating severe asthma

April 2023

TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

TA877 - Finerenone for treating chronic kidney disease in type 2 diabetes

TA876 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer

TA875 - Semaglutide for managing overweight and obesity

 

Back to top